Q3 FY26 Concall · Feb 13, 2026
Shaily Engineering Plastics Q3 FY26 Concall Decoded:
GLP-1 Pens Go Brrr, But High-Speed Lines Go ‘Qualification Dance’
A plastic pen maker that grew revenue 27%, EBITDA 43%, opened a ₹350-crore Abu Dhabi factory, and somehow convinced 100-year-old investors that waiting 18 months for capacity is actually a feature, not a bug.
Q3 Revenue₹251 Cr
Revenue Growth+27% YoY
EBITDA Growth+43% YoY
EBITDA Margin26.5%
PAT Growth+48% YoY
01 — Opening Hook
The Plastic Surgeon of Pharma Devices
Imagine a company that makes plastic pens for diabetics and cardiac patients. Imagine they just told the market: “We’re building a ₹350-crore factory in Abu Dhabi, hiring a COO from Taiwan who managed 7 manufacturing plants, and we’ve already sold 65-75% of the capacity to customers we can’t name.” Then imagine investors ask: “But when will this thing actually run?” And management says: “Dude, ask us in 18 months.” Welcome to Shaily—where GLP-1 mania meets manufacturing reality.
Q3 FY26 delivered the kind of numbers that make PowerPoint slides glow: ₹251 crores revenue (+27% YoY), ₹66 crores EBITDA (+43% YoY), 26.5% margins. Healthcare segment now 42% of the pie. But here’s the joke: the company’s main assembly line is still in “qualification”—which is corporate-speak for “we built a Ferrari but it’s still learning to drive.” Read on to decode what happens when a plastic molds company becomes a GLP-1 monopoly play.
Heads Up: Management committed ₹300-350 crores capex for Abu Dhabi without issuing shares. Debt stays low, but this is a calculated bet that Ozempic demand never cools off. It won’t. But competition will. Margins always do.
02 — At a Glance
The Quarterly Plastic Fantastic
Q3 Revenue
₹251 Cr
+27% YoY. Healthcare alone grew 139%. Everything else is rounding error.
EBITDA Growth
+43% YoY
₹66 Cr. Margin 26.5%. The GLP-1 business prints money. Consumer segment bleeds it.
PAT Growth
+48% YoY
₹37 Cr net profit. Shareholders go brrrr. Capex approval goes brrrr harder.
9M FY26 EBITDA
+76% YoY
₹218 Cr. 29% margin. The margin expansion story is real—not a mirage.
Cash PAT 9M
₹166 Cr
+73% YoY. Working capital wasn’t screaming. Yet.
The Reality Check: Revenue up 27%, profit up 48%. Margins expanding. But this is a one-product-line story with gestation delays baked in. Scale now, regret pricing later. It’s the Semaglutide tango.
03 — Management’s Key Commentary
What They Said (And What It Actually Means)
Members get full access to every article.
